Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP044: Active disease on intestinal ultrasound in pregnancy is associated with an increased risk of adverse obstetric and neonatal outcomes: an international multi-centre prospective cohort study.ECCO'25 Berlin
Year: 2025
Authors: Flanagan, Emma
DOP045: Novel AI-Driven Detection, Localisation and Quantification of Neutrophils for Prediction of Early Response to Therapy in a Phase 2 Ulcerative Colitis Clinical TrialECCO'25 Berlin
Year: 2025
Authors: Iacucci, Marietta
DOP046: Effectiveness and Safety of Mirikizumab after switching from Ustekinumab in patients with moderate to severe Crohn’s disease: results from a long-term extension studyECCO'25 Berlin
Year: 2025
Authors: D'Haens, Geert
DOP047: Effectiveness of second-and-third line biologics in perianal Crohn’s disease (pCD) – a multicenter propensity score-matched studyECCO'25 Berlin
Year: 2025
Authors: Shani, Uria
DOP048: Efficacy and safety of dose de-escalation from 50 mg to 25 mg QD of obefazimod maintenance treatment: Analysis of a subset of patients with moderately to severely active ulcerative colitis (UC) who have completed 2 years with 25mg QDECCO'25 Berlin
Year: 2025
Authors: Danese, Silvio
DOP049: Vedolizumab is more effective at inducing histo-endoscopic healing in early Crohn’s Disease compared to late CD, with comparable healing rates regardless of disease location: data from the LOVE-CD trialECCO'25 Berlin
Year: 2025
Authors: Lenfant, Matthias
DOP050: Target achievement after 48 weeks of vedolizumab treatment in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trialECCO'25 Berlin
Year: 2025
Authors: Jairath, Vipul
DOP051: Upadacitinib for induction of remission in pediatric Ulcerative Colitis: An international multi‑center studyECCO'25 Berlin
Year: 2025
Authors: Yerushalmy-Feler, Anat
DOP052: Etrasimod as induction and maintenance therapy in Asian patients with moderately to severely active Ulcerative Colitis: Results from the maintenance period of a randomised, double-blind, placebo-controlled, multi-centre Phase 3 study (ES101002)ECCO'25 Berlin
Year: 2025
Authors: Zhong, Jie
DOP053: Efficacy of appendectomy in inducing remission in moderate-to-severe ulcerative colitis: preliminary one year results of a multicentre prospective cohort study (COSTA)ECCO'25 Berlin
Year: 2025
Authors: Visser, Eva
DOP054: Early Histologic Response and Remission are Associated With Objective Control of Inflammation After One Year of Treatment With Mirikizumab in Moderately-to-Severely Active Crohn’s DiseaseECCO'25 Berlin
Year: 2025
Authors: Magro, Fernando
DOP055: Upadacitinib for induction of remission in pediatric Crohn’s disease: An international multicenter studyECCO'25 Berlin
Year: 2025
Authors: Yerushalmy-Feler, Anat
DOP056: TDM-Based Dose-Intensification of Infliximab is not Superior to Standard Dosing in Patients with Acute Severe Ulcerative Colitis: Results from the TITRATE StudyECCO'25 Berlin
Year: 2025
Authors: Van Oostrom, Joep
DOP057: Early serum and faecal cytokines predict clinical outcomes in Acute Severe Ulcerative Colitis: results from PREDICT-UCECCO'25 Berlin
Year: 2025
Authors: Li Wai Suen, Christopher
DOP058: Efficacy and Safety of Vedolizumab Combined with Upadacitinib in Moderate-to-Severe Ulcerative Colitis: A Multicenter, Prospective, Randomized Controlled TrialECCO'25 Berlin
Year: 2025
Authors: Zhi, Min
DOP059: Lack of significance of treatment-emergent anti-drug antibodies on efficacy of mirikizumab in patients with moderately-to-severely active Crohn’s Disease: Results from the VIVID-1 studyECCO'25 Berlin
Year: 2025
Authors: Vermeire, Séverine
DOP060: Early disease efficacy of guselkumab therapy in biologic-naïve patients with moderately to severely active Crohn’s disease: Post-hoc analysis from the phase 3 GALAXI 2 & 3 studiesECCO'25 Berlin
Year: 2025
Authors: D'Haens, Geert
DOP061: RO7790121 shows early and rapid symptomatic remission in the treatment of moderately to severely active ulcerative colitis – Findings from the phase IIb TUSCANY-2 trialECCO'25 Berlin
Year: 2025
Authors: Yarur, Andres
DOP062: Quantitative histologic features of the inflammatory microenvironment using digital pathology prior to adalimumab treatment allows prediction of response in patients with Ulcerative Colitis.ECCO'25 Berlin
Year: 2025
Authors: Shamshoian, John
DOP063: Hospitalised severe ulcerative colitis patients treated with rescue infliximab risk treatment failure due to underexposure caused by high drug clearanceECCO'25 Berlin
Year: 2025
Authors: Kloft, Charlotte